PDSB - PDS Biotechnology Corp (PDSB) - ASCO Presentation Updates VERSATILE-002 Data

Phase 2 VERSATILE Study Data To Be Presented. PDS Biotech will be making two data presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 3-7. A poster presentation of preliminary data from the Phase 2 VERSATILE-002 clinical trial is scheduled for June 6.PDS0101 Data From Phase 2 Trial In Head and Neck Cancer. VERSATILE-002 is a Phase 2 trial testing PDS0101 in HPV-positive head and neck squamous cell carcinoma (HNSCC). It is a single-arm study administering PDS0101 in combination with the PD-1 checkpoint inhibitor pembrolizumab (Keytruda, from Merck). The data includes efficacy assessment of 17 patients and safety assessment of 19 patients at a prespecified analysis point. Read More >>